Code: 01321923

Nonclinical Development of Novel Biologics, Biosimilars, Vac

Name: Nonclinical Development of Novel Biologics, Biosimilars, Vac
Brand: Academic Press
SKU: 01321923
Price: 208.67 EUR
Availability: BackOrder

by Lisa M Plitnick

Language: English
Binding: Hardback
Number of pages: 432
Publisher: Academic Press, 2013
More about this

208.67 €

Availability:

50/50

We think title might be available. Upon your order we will do our best to get it within 6 weeks.
We search the world

Availability alert

Add to wishlist

Women of Lilac Street
22.66 €
Buy
The Dark
15.85 € -21 %
Buy
Reviews of Environmental Contamination and Toxicology 196
179.30 €
Buy
Circuit Techniques for Low-Voltage and High-Speed A/D Converters
231.44 €
Buy
Biologics and Biosimilars
28.65 €
Buy
Design Patterns
53.35 € -1 %
Buy
Understanding Bioinformatics
113.33 € -5 %
Buy

Give this book as a present today

Order book and choose Gift Order.
We will send you book gift voucher at once. You can give it out to anyone.
Book will be send to donee, nothing more to care about.

Book gift voucher sample Read more

Availability alert

We will watch availability for you

Enter your e-mail address and once book will be available,
we will send you a message. It's that simple.

More about Nonclinical Development of Novel Biologics, Biosimilars, Vac

Book details
Synopsis
Trending among others

You get 519 loyalty points

Book synopsis

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics. It provides in-depth coverage of the process of nonclinical safety assessment and comprehensive reviews of each type of biopharmaceutical. It contains the most pertinent international regulatory guidance documents for nonclinical evaluation. It covers early de-risking strategies and designs of safety assessment programs for novel biopharmaceuticals and vaccines, as well as follow-on biologics or "biosimilars". It offers a multi-authored book with chapters written by qualified experts in their respective fields.